These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33141415)

  • 1. Real-World Economic Burden Among Patients With And Without Heart Failure Worsening After Cardiac Resynchronization Therapy.
    Chung ES; Rickard J; Lu X; DerSarkissian M; Zichlin ML; Cheung HC; Swartz N; Greatsinger A; Duh MS
    Adv Ther; 2021 Jan; 38(1):441-467. PubMed ID: 33141415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between use of an Adaptive Cardiac Resynchronization Therapy Algorithm and Healthcare Utilization and Cost.
    Gold MR; Zhou J; Higuera L; Lanctin DP; Chung ES
    J Card Fail; 2024 Jul; ():. PubMed ID: 38977056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world clinical burden among patients with and without heart failure worsening after cardiac resynchronization therapy.
    Chung ES; Rickard J; Lu X; DerSarkissian M; Zichlin ML; Cheung HC; Swartz N; Greatsinger A; Duh MS
    Curr Med Res Opin; 2022 Sep; 38(9):1489-1498. PubMed ID: 35727103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost of non-response to cardiac resynchronization therapy: characterizing heart failure events following cardiac resynchronization therapy.
    Varma N; Auricchio A; Connolly AT; Boehmer J; Bahu M; Costanzo MR; Leonelli F; Yoo D; Singh J; Nabutovsky Y; Gold M
    Europace; 2021 Oct; 23(10):1586-1595. PubMed ID: 34198334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Association of serum albumin level and clinical outcomes among heart failure patients receiving cardiac resynchronization therapy].
    Yang SW; Liu ZM; Mi JR; Liu SY; Ding LG; Chen KP; Hua W; Zhang S
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Mar; 45(3):204-208. PubMed ID: 28316176
    [No Abstract]   [Full Text] [Related]  

  • 6. Economic Value and Cost-Effectiveness of Cardiac Resynchronization Therapy Among Patients With Mild Heart Failure: Projections From the REVERSE Long-Term Follow-Up.
    Gold MR; Padhiar A; Mealing S; Sidhu MK; Tsintzos SI; Abraham WT
    JACC Heart Fail; 2017 Mar; 5(3):204-212. PubMed ID: 28254126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and Economic Burden of Chronic Heart Failure and Reduced Ejection Fraction Following a Worsening Heart Failure Event.
    Butler J; Djatche LM; Sawhney B; Chakladar S; Yang L; Brady JE; Yang M
    Adv Ther; 2020 Sep; 37(9):4015-4032. PubMed ID: 32761552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Timing of cardiac resynchronization therapy device implantation in heart failure patients and its association with outcomes.
    Goldstein SA; Mentz RJ; Hellkamp AS; Randolph TC; Fonarow GC; Hernandez A; Yancy CW; Al-Khatib SM
    Clin Cardiol; 2019 Feb; 42(2):256-263. PubMed ID: 30548280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Extrapolation of Clinical Benefits Among Patients With Mild Heart Failure Receiving Cardiac Resynchronization Therapy: Analysis of the 5-Year Follow-Up From the REVERSE Study.
    Gold MR; Padhiar A; Mealing S; Sidhu MK; Tsintzos SI; Abraham WT
    JACC Heart Fail; 2015 Sep; 3(9):691-700. PubMed ID: 26277764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation.
    Colquitt JL; Mendes D; Clegg AJ; Harris P; Cooper K; Picot J; Bryant J
    Health Technol Assess; 2014 Aug; 18(56):1-560. PubMed ID: 25169727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction).
    Linde C; Mealing S; Hawkins N; Eaton J; Brown B; Daubert JC;
    Eur Heart J; 2011 Jul; 32(13):1631-9. PubMed ID: 21112898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation of QRS Duration to Clinical Benefit of Cardiac Resynchronization Therapy in Mild Heart Failure Patients Without Left Bundle Branch Block: The Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy Substudy.
    Biton Y; Kutyifa V; Cygankiewicz I; Goldenberg I; Klein H; McNitt S; Polonsky B; Ruwald AC; Ruwald MH; Moss AJ; Zareba W
    Circ Heart Fail; 2016 Feb; 9(2):e002667. PubMed ID: 26823498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex Differences in Long-Term Outcomes With Cardiac Resynchronization Therapy in Mild Heart Failure Patients With Left Bundle Branch Block.
    Biton Y; Zareba W; Goldenberg I; Klein H; McNitt S; Polonsky B; Moss AJ; Kutyifa V;
    J Am Heart Assoc; 2015 Jun; 4(7):. PubMed ID: 26124205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is the cost of non-response to cardiac resynchronization therapy? Hospitalizations and healthcare utilization in the CRT-D population.
    Corbisiero R; Buck DC; Muller D; Bharmi R; Dalal N; Kazemian P
    J Interv Card Electrophysiol; 2016 Nov; 47(2):189-195. PubMed ID: 27613184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple Comorbidities and Response to Cardiac Resynchronization Therapy: MADIT-CRT Long-Term Follow-Up.
    Zeitler EP; Friedman DJ; Daubert JP; Al-Khatib SM; Solomon SD; Biton Y; McNitt S; Zareba W; Moss AJ; Kutyifa V
    J Am Coll Cardiol; 2017 May; 69(19):2369-2379. PubMed ID: 28494974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Patterns Among Patients With Mantle Cell Lymphoma and Comparison of Healthcare Resource Utilization and Costs Among Relapsed/Refractory Patients Treated With Ibrutinib or Chemoimmunotherapy: A Real-world Retrospective Study.
    Ghosh N; Emond B; Lafeuille MH; Côté-Sergent A; Lefebvre P; Huang Q
    Clin Ther; 2021 Aug; 43(8):1285-1299. PubMed ID: 34332789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization of cardiac resynchronization therapy in eligible patients hospitalized for heart failure and its association with patient outcomes.
    Randolph TC; Hellkamp AS; Zeitler EP; Fonarow GC; Hernandez AF; Thomas KL; Peterson ED; Yancy CW; Al-Khatib SM
    Am Heart J; 2017 Jul; 189():48-58. PubMed ID: 28625381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyponatremia as a predictor for worsening heart failure in patients receiving cardiac resynchronization therapy.
    Arao K; Fujiwara T; Sakakura K; Wada H; Sugawara Y; Suga C; Ako J; Ishikawa SE; Momomura S
    Circ J; 2013; 77(1):116-22. PubMed ID: 23018767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome: the MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy) study.
    Hsu JC; Solomon SD; Bourgoun M; McNitt S; Goldenberg I; Klein H; Moss AJ; Foster E;
    J Am Coll Cardiol; 2012 Jun; 59(25):2366-73. PubMed ID: 22698490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of cardiac resynchronization therapy in Greece: an analysis based on the CArdiac REsychronization in Heart Failure trial.
    Maniadakis N; Ekman M; Calvert MJ; Freemantle N; Karamalis M; Vardas P
    Europace; 2011 Nov; 13(11):1597-603. PubMed ID: 21821852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.